Cadila Healthcare Limited, a global pharmaceuticals company, and its subsidiary Zydus Pharmaceuticals (USA) Inc., a leading generic pharmaceutical company in the United States, have finalized an agreement with Upsher-Smith Laboratories, Inc. to settle all outstanding patent litigation related to Qudexy XR (topiramate) extended-release capsules.
Under the terms of the agreement, Upsher-Smith grants Zydus a license to market Zydus’ generic version of Qudexy XR beginning on March 19, 2020, or earlier under certain circumstances. Other terms of the settlement were not disclosed.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.